ESC Kongress 2024: INFINITY-SWEDEHEART-Studie mit dem DynamX-Bioadaptor von Elixir Medical erreicht primären Endpunkt und klinische Ergebnisse bestätigen einzigartigen Wirkmechanismus
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
ESC Kongress 2024: INFINITY-SWEDEHEART-Studie mit dem DynamX-Bioadaptor von Elixir Medical erreicht primären Endpunkt und klinische Ergebnisse bestätigen einzigartigen Wirkmechanismus Größter...
Congreso ESC 2024: El ensayo INFINITY-SWEDEHEART del bioadaptador DynamX de Elixir Medical alcanza el criterio de valoración principal y los resultados clínicos confirman su exclusivo mecanismo de acción
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congreso ESC 2024: El ensayo INFINITY-SWEDEHEART del bioadaptador DynamX de Elixir Medical alcanza el criterio de valoración principal y los resultados clínicos confirman su exclusivo mecanismo de...
Congresso ESC 2024: lo studio INFINITY-SWEDEHEART relativo al DynamX Bioadaptor di Elixir Medical soddisfa l’endpoint primario e i risultati clinici confermano un meccanismo d’azione unico
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congresso ESC 2024: lo studio INFINITY-SWEDEHEART relativo al DynamX Bioadaptor di Elixir Medical soddisfa l’endpoint primario e i risultati clinici confermano un meccanismo d’azione unico — La più...
Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action...
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
September 02, 2024 07:45 ET
|
Elixir Medical Corporation
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action —Largest randomized data set to...
CommerceTel Announces Record Second Quarter 2012 Financial Results
August 15, 2012 09:00 ET
|
CommerceTel Corp.
SAN DIEGO, CA--(Marketwire - Aug 15, 2012) - CommerceTel Corporation (OTCBB: MFON), an award-winning provider of proprietary mobile marketing technologies and solutions, announced today record...
CommerceTel to Present at the Inaugural Marcum MicroCap Conference on June 20th in NYC
June 12, 2012 08:30 ET
|
CommerceTel Corporation
SAN DIEGO, CA--(Marketwire - Jun 12, 2012) - CommerceTel Corporation (OTCBB: MFON), an award-winning provider of proprietary mobile marketing technologies and solutions, today announced that CEO...
CommerceTel Announces Two New Independent Board Members
June 07, 2012 09:30 ET
|
CommerceTel Corporation
CHANDLER, AZ--(Marketwire - Jun 7, 2012) - CommerceTel Corporation (OTCBB: MFON), an award-winning provider of proprietary mobile marketing technologies and solutions, today announced that Mr....
CommerceTel Announces Corporate Update; Projecting 2012 YoY Revenue Growth of At Least 60%
June 06, 2012 10:14 ET
|
CommerceTel Corporation
SAN DIEGO, CA--(Marketwire - Jun 6, 2012) - CommerceTel Corporation (OTCBB: MFON), an award-winning provider of proprietary mobile marketing technologies and solutions, today announced an update on...
CommerceTel Completes $4.3 Million Financing
June 05, 2012 07:30 ET
|
CommerceTel Corporation
SAN DIEGO, CA--(Marketwire - Jun 5, 2012) - CommerceTel Corporation (OTCBB: MFON), an award-winning provider of proprietary mobile marketing technologies and solutions, today announced that it has...